Download PDF
Thromb Haemost 2022; 122(08): 1255-1264
DOI: 10.1055/a-1711-1263
Review Article

Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review

Ilia Makedonov
1   Department of Medicine, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
,
Susan R. Kahn
2   Department of Medicine and Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
,
Jameel Abdulrehman
3   Division of Hematology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada
,
Sam Schulman 
4   Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Aurelien Delluc 
5   Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada
6   Division of Hematology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada
,
Peter Gross
7   Department of Medicine, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
Jean-Philippe Galanaud
8   Department of Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

The postthrombotic syndrome (PTS) is chronic venous insufficiency secondary to a prior deep vein thrombosis (DVT). It is the most common complication of venous thromboembolism (VTE) and, while not fatal, it can lead to chronic, unremitting symptoms as well as societal and economic consequences. The cornerstone of PTS treatment lies in its prevention after DVT. Specific PTS preventative measures include the use of elastic compression stockings and pharmacomechanical catheter-directed thrombolysis. However, the efficacy of these treatments has been questioned by large randomized controlled trials (RCTs). So far, anticoagulation, primarily prescribed to prevent DVT extension and recurrence, appears to be the only unquestionably effective treatment for the prevention of PTS. In this literature review we present pathophysiological, biological, radiological, and clinical data supporting the efficacy of anticoagulants to prevent PTS and the possible differential efficacy among available classes of anticoagulants (vitamin K antagonists [VKAs], low molecular weight heparins [LMWHs] and direct oral anticoagulants [DOACs]). Data suggest that LMWHs and DOACs are superior to VKAs, but no head-to-head comparison is available between DOACs and LMWHs. Owing to their potentially greater anti-inflammatory properties, LMWHs could be superior to DOACs. This finding may be of interest particularly in patients with extensive DVT at high risk of moderate to severe PTS, but needs to be confirmed by a dedicated RCT.

Keywords

postthrombotic syndrome - venous thrombosis - low molecular weight heparin - vitamin K-dependent factors - direct oral anticoagulants

Supplementary Material



Publication History

Received: 13 July 2021

Accepted: 24 November 2021

Accepted Manuscript online:
01 December 2021

Article published online:
15 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Makedonov I, Kahn SR, Galanaud J-P. Prevention and management of the post-thrombotic syndrome. J Clin Med 2020; 9 (04) 923
    CrossrefPubMedGoogle Scholar
  • 2 Kachroo S, Boyd D, Bookhart BK. et al. Quality of life and economic costs associated with postthrombotic syndrome. Am J Health Syst Pharm 2012; 69 (07) 567-572
    CrossrefPubMedGoogle Scholar
  • 3 Guanella R, Ducruet T, Johri M. et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost 2011; 9 (12) 2397-2405
    CrossrefPubMedGoogle Scholar
  • 4 Lubberts B, Paulino Pereira NR, Kabrhel C, Kuter DJ, DiGiovanni CW. What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis. Thromb Haemost 2016; 116 (03) 417-431
    PubMedGoogle Scholar
  • 5 Kahn SR, Shbaklo H, Lamping DL. et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6 (07) 1105-1112
    CrossrefPubMedGoogle Scholar
  • 6 MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63 (20, Suppl 6): S5-S15
    CrossrefPubMedGoogle Scholar
  • 7 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e419S-e496S
    PubMedGoogle Scholar
  • 8 Kahn SR, Shapiro S, Wells PS. et al; SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383 (9920): 880-888
    CrossrefPubMedGoogle Scholar
  • 9 Vedantham S, Goldhaber SZ, Julian JA. et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377 (23) 2240-2252
    CrossrefPubMedGoogle Scholar
  • 10 Galanaud JP, Righini M, Quéré I. Compression stockings to prevent post-thrombotic syndrome. Lancet 2014; 384 (9938): 129
    CrossrefPubMedGoogle Scholar
  • 11 ten Cate-Hoek AJ. Elastic compression stockings–is there any benefit?. Lancet 2014; 383 (9920): 851-853
    CrossrefPubMedGoogle Scholar
  • 12 Kahn SR, Comerota AJ, Cushman M. et al; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130 (18) 1636-1661
    CrossrefPubMedGoogle Scholar
  • 13 Galanaud JP, Laroche JP, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost 2013; 11 (03) 402-411
    CrossrefPubMedGoogle Scholar
  • 14 Bauer G. Thrombosis; early diagnosis and abortive treatment with heparin. Lancet 1946; 1 (6396): 447-454
    CrossrefPubMedGoogle Scholar
  • 15 van Dongen CJJ, Prandoni P, Frulla M, Marchiori A, Prins MH, Hutten BA. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005; 3 (05) 939-942
    CrossrefPubMedGoogle Scholar
  • 16 Chitsike RS, Rodger MA, Kovacs MJ. et al. Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemost 2012; 10 (10) 2039-2044
    CrossrefPubMedGoogle Scholar
  • 17 Galanaud JP, Righini M, Le Collen L. et al. Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: the CACTUS-PTS study. J Thromb Haemost 2020; 18 (04) 857-864
    CrossrefPubMedGoogle Scholar
  • 18 Bradbury C, Fletcher K, Sun Y. et al. A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study). Br J Haematol. 2019: bjh.16275
    PubMedGoogle Scholar
  • 19 Schulman S, Lindmarker P, Holmström M. et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (04) 734-742
    CrossrefPubMedGoogle Scholar
  • 20 van Rij AM, Hill G, Krysa J. et al. Prospective study of natural history of deep vein thrombosis: early predictors of poor late outcomes. Ann Vasc Surg 2013; 27 (07) 924-931
    CrossrefPubMedGoogle Scholar
  • 21 Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis (Review) summary of findings for the main comparison. Cochrane Database Syst Rev 2016; 1-59
    PubMedGoogle Scholar
  • 22 Rabinovich A, Cohen JM, Cushman M. et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. J Thromb Haemost 2015; 13 (03) 398-408
    CrossrefPubMedGoogle Scholar
  • 23 Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008; 28 (03) 387-391
    CrossrefPubMedGoogle Scholar
  • 24 Mosevoll KA, Johansen S, Wendelbo Ø, Nepstad I, Bruserud Ø, Reikvam H. Cytokines, adhesion molecules, and matrix metalloproteases as predisposing, diagnostic, and prognostic factors in venous thrombosis. Front Med (Lausanne) 2018; 5: 147
    CrossrefPubMedGoogle Scholar
  • 25 Nicklas JM, Gordon AE, Henke PK. Resolution of deep venous thrombosis: proposed immune paradigms. Int J Mol Sci 2020; 21 (06) 1-24
    CrossrefPubMedGoogle Scholar
  • 26 Borgel D, Bianchini E, Lasne D, Pascreau T, Saller F. Inflammation in deep vein thrombosis: a therapeutic target?. Hematology 2019; 24 (01) 742-750
    CrossrefPubMedGoogle Scholar
  • 27 Jezovnik MK, Poredos P. Factors influencing the recanalisation rate of deep venous thrombosis. Int Angiol 2012; 31 (02) 169-175
    PubMedGoogle Scholar
  • 28 Roumen-Klappe EM, Janssen MCH, Van Rossum J. et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost 2009; 7 (04) 582-587
    CrossrefPubMedGoogle Scholar
  • 29 Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb Haemost 2009; 101 (03) 505-512
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Deatrick KB, Elfline M, Baker N. et al. Postthrombotic vein wall remodeling: preliminary observations. J Vasc Surg 2011; 53 (01) 139-146
    CrossrefPubMedGoogle Scholar
  • 31 de Franciscis S, Gallelli L, Amato B. et al. Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome?. Int Wound J 2016; 13 (06) 1237-1245
    CrossrefPubMedGoogle Scholar
  • 32 Henke PK, Varma MR, Moaveni DK. et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. Thromb Haemost 2007; 98 (05) 1045-1055
    PubMedGoogle Scholar
  • 33 Betensky M, Amankwah EK, Brandal S, Everett AD, Goldenberg NA. Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank. Blood Adv 2021; 5 (01) 233-239
    CrossrefPubMedGoogle Scholar
  • 34 Holbrook AM, Pereira JA, Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165 (10) 1095-1106
    CrossrefPubMedGoogle Scholar
  • 35 Popov Aleksandrov A, Mirkov I, Ninkov M. et al. Effects of warfarin on biological processes other than haemostasis: a review. Food Chem Toxicol 2018; 113: 19-32
    CrossrefPubMedGoogle Scholar
  • 36 Rios-Doria J, Favata M, Lasky K. et al. A Potent and selective dual inhibitor of AXL and MERTK possesses both immunomodulatory and tumor-targeted activity. Front Oncol 2020; 10: 598477
    CrossrefPubMedGoogle Scholar
  • 37 Belij S, Miljković D, Popov A. et al. Effects of subacute oral warfarin administration on peripheral blood granulocytes in rats. Food Chem Toxicol 2012; 50 (05) 1499-1507
    CrossrefPubMedGoogle Scholar
  • 38 Mirkov I, Popov Aleksandrov A, Demenesku J. et al. Intestinal toxicity of oral warfarin intake in rats. Food Chem Toxicol 2016; 94: 11-18
    CrossrefPubMedGoogle Scholar
  • 39 Eichbaum FW, Slemer O, Zyngier SB. Anti-inflammatory effect of warfarin and vitamin K1. Naunyn Schmiedebergs Arch Pharmacol 1979; 307 (02) 185-190
    CrossrefPubMedGoogle Scholar
  • 40 Yan Y, Ji Y, Su N. et al. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: a review. Carbohydr Polym 2017; 160: 71-81
    CrossrefPubMedGoogle Scholar
  • 41 Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. Pharmaceuticals (Basel) 2016; 9 (03) 9
    CrossrefPubMedGoogle Scholar
  • 42 Moaveni DK, Lynch EM, Luke C. et al. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin. J Vasc Surg 2008; 47 (03) 616-624
    CrossrefPubMedGoogle Scholar
  • 43 Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ, Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg 1998; 28 (05) 848-854
    CrossrefPubMedGoogle Scholar
  • 44 Ceccarelli M, Bani D, Cinci L. et al. Anti-inflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med 2009; 13 (8B) 2704-2712
    CrossrefPubMedGoogle Scholar
  • 45 Bal Dit Sollier C, Drouet L. Non anticoagulant properties of heparin preparations: practical considerations. Sang Thromb. Vaiss. 2013; 25: 389-398
    CrossrefPubMedGoogle Scholar
  • 46 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same?. Semin Thromb Hemost 1996; 22 (Suppl. 01) 77-91
    PubMedGoogle Scholar
  • 47 Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110 (01) 127-136
    CrossrefPubMedGoogle Scholar
  • 48 Ranjbaran H, Wang Y, Manes TD. et al. Heparin displaces interferon-γ-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 2006; 114 (12) 1293-1300
    CrossrefPubMedGoogle Scholar
  • 49 Bârzu T, Lormeau J-C, Petitou M, Michelson S, Choay J. Heparin-derived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells. J Cell Physiol 1989; 140 (03) 538-548
    CrossrefPubMedGoogle Scholar
  • 50 Deepa PR, Varalakshmi P. Influence of a low-molecular-weight heparin derivative on the nitric oxide levels and apoptotic DNA damage in adriamycin-induced cardiac and renal toxicity. Toxicology 2006; 217 (2-3): 176-183
    CrossrefPubMedGoogle Scholar
  • 51 Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114 (02) 79-102
    CrossrefPubMedGoogle Scholar
  • 52 Thanaporn P, Myers DD, Wrobleski SK. et al. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery 2003; 134 (02) 365-371
    CrossrefPubMedGoogle Scholar
  • 53 Rectenwald JE, Deatrick KB, Sukheepod P. et al. Experimental pulmonary embolism: effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin. J Vasc Surg 2006; 43 (04) 800-808
    CrossrefPubMedGoogle Scholar
  • 54 Kakkar VV, Hoppenstead DA, Fareed J. et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002; 99 (06) 1965-1970
    CrossrefPubMedGoogle Scholar
  • 55 Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20 (05) 521-526
    CrossrefPubMedGoogle Scholar
  • 56 Gonzalez-Fajardo JA, Arreba E, Castrodeza J. et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30 (02) 283-292
    CrossrefPubMedGoogle Scholar
  • 57 Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P. Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003; 89 (04) 674-680
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 López-Beret P, Orgaz A, Fontcuberta J. et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33 (01) 77-90
    CrossrefPubMedGoogle Scholar
  • 59 Daskalopoulos MEM, Daskalopoulou SS, Tzortzis E. et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29 (06) 638-650
    CrossrefPubMedGoogle Scholar
  • 60 Romera A, Cairols MA, Vila-Coll R. et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009; 37 (03) 349-356
    CrossrefPubMedGoogle Scholar
  • 61 González-Fajardo JA, Martin-Pedrosa M, Castrodeza J, Tamames S, Vaquero-Puerta C. Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin. J Vasc Surg 2008; 48 (04) 953-959
    CrossrefPubMedGoogle Scholar
  • 62 Hull RD, Pineo GF, Brant R. et al; LITE Trial Investigators. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009; 122 (08) 762-769
    CrossrefPubMedGoogle Scholar
  • 63 Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med 2011; 124 (08) 756-765
    CrossrefPubMedGoogle Scholar
  • 64 Guillou S, Beaumont J, Tamareille S. et al. Direct rivaroxaban-induced factor Xa inhibition proves to be cardioprotective in rats. Shock 2020; 53 (06) 730-736
    CrossrefPubMedGoogle Scholar
  • 65 Hara T, Fukuda D, Tanaka K. et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242 (02) 639-646
    CrossrefPubMedGoogle Scholar
  • 66 Blessing E, Zhou Q, Bea F. et al Evaluation of plaque stability of advanced atherosclerotic lesions in Apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011. 2011
    PubMedGoogle Scholar
  • 67 Laurent M, Joimel U, Varin R. et al. Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release. Exp Hematol Oncol 2014; 3 (01) 30
    CrossrefPubMedGoogle Scholar
  • 68 Ellinghaus P, Perzborn E, Hauenschild P. et al. Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res 2016; 142: 44-51
    CrossrefPubMedGoogle Scholar
  • 69 Paar V, Jirak P, Gruber S. et al. Influence of dabigatran on pro-inflammatory cytokines, growth factors and chemokines - slowing the vicious circle of coagulation and inflammation. Life Sci 2020; 262: 118474
    CrossrefPubMedGoogle Scholar
  • 70 Chan MY, Lin M, Lucas J. et al. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost 2012; 108 (06) 1180-1191
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Prandoni P, Ageno W, Mumoli N. et al. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res 2017; 153: 97-100
    CrossrefPubMedGoogle Scholar
  • 72 Ferreira T, Huber SC, de Moraes Martinelli B. et al. Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban. Vasc Pharmacol 2019. 106608
    Google Scholar
  • 73 Houghton DE, Lekah A, Macedo TA. et al. Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin. J Thromb Thrombolysis 2020; 49 (02) 199-205
    CrossrefPubMedGoogle Scholar
  • 74 Piati PK, Peres AK, de Andrade DO, Jorge MA, Toregeani JF. Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban. J Vasc Bras 2019; 18: e20180111
    PubMedGoogle Scholar
  • 75 de Athayde Soares R, Matielo MF, Brochado Neto FC, Nogueira MP, Almeida RD, Sacilotto R. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery 2019; 166 (06) 1076-1083
    CrossrefPubMedGoogle Scholar
  • 76 Prandoni P, Ageno W, Ciammaichella M. et al; DOAC-PTS Investigators. The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. Intern Emerg Med 2020; 15 (03) 447-452
    CrossrefPubMedGoogle Scholar
  • 77 Utne KK, Dahm A, Wik HS, Jelsness-Jørgensen LP, Sandset PM, Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res 2018; 163: 6-11
    CrossrefPubMedGoogle Scholar
  • 78 Jeraj L, Jezovnik MK, Poredos P. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thromb Res 2017; 157: 46-48
    CrossrefPubMedGoogle Scholar
  • 79 Cheung YW, Middeldorp S, Prins MH. et al; Einstein PTS Investigators Group. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost 2016; 116 (04) 733-738
    PubMedGoogle Scholar
  • 80 Wik H, Sandset P, Eriksson H. et al. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin - a long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemost 2021; 19 (10) 2495-2503
    CrossrefPubMedGoogle Scholar
  • 81 Coleman CI, Beyer-Westendorf J, Bunz TJ, Mahan CE, Spyropoulos AC. Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism. Clin Appl Thromb Hemost 2018; 24 (04) 575-582
    CrossrefPubMedGoogle Scholar
  • 82 Søgaard M, Nielsen PB, Skjøth F, Kjældgaard JN, Coleman CI, Larsen TB. Rivaroxaban versus warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism. Am J Med 2018; 131 (07) 787-794
    CrossrefPubMedGoogle Scholar
  • 83 Li R, Yuan M, Cheng J. et al. Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis. Thromb Res 2020; 196: 340-348
    CrossrefPubMedGoogle Scholar
  • 84 Camporese G, Bernardi E, Bortoluzzi C. et al. MAC project-monitoring anticoagulant therapy observational study: rationale and protocol. Front Med (Lausanne) 2021; 7: 584459
    CrossrefPubMedGoogle Scholar
  • 85 Salta S, Papageorgiou L, Larsen AK. et al. Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots. Res Pract Thromb Haemost 2018; 2 (04) 696-707
    CrossrefPubMedGoogle Scholar
  • 86 Baglin T. Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins?. J Thromb Haemost 2012; 10 (08) 1702-1703
    CrossrefPubMedGoogle Scholar
  • 87 Nicolaides A, Hull RD, Fareed J. Cardiovascular Disease Educational and Research Trust, European Venous Forum, North American Thrombosis Forum, International Union of Angiology and Union Internationale du Phlebologie. Prevention of postthrombotic syndrome. Clin Appl Thromb Hemost 2013; 19 (02) 213-215
    CrossrefPubMedGoogle Scholar
  • 88 Hull RD, Townshend G. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Thromb Haemost 2013; 110 (01) 14-22
    PubMedGoogle Scholar
  • 89 Rabinovich A, Ducruet T, Kahn SR. SOX Trial investigators. Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis. J Thromb Haemost 2018; 16 (02) 262-270
    CrossrefPubMedGoogle Scholar
  • 90 Amin EE, van Kuijk SMJ, Joore MA, Prandoni P, Ten Cate H, Ten Cate-Hoek AJ. Development and validation of a practical two-step prediction model and clinical risk score for post-thrombotic syndrome. Thromb Haemost 2018; 118 (07) 1242-1249
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Méan M, Limacher A, Alatri A, Aujesky D, Mazzolai L. Derivation and validation of a prediction model for risk stratification of post-thrombotic syndrome in elderly patients with a first deep vein thrombosis. Thromb Haemost 2018; 118 (08) 1419-1427
    Article in Thieme ConnectPubMedGoogle Scholar